Replies to post #2426 on Dendreon Corp fka DNDNQ

[walldiver]

IMO, Hussain purposely failed to mention that the asymptomatic patients in the TAX327 trial showed a 3.2-month median survival benefit. In other words, DNDN's "failed" 9902a trial still beat TAX327 in median survival.